Alps Group launches drug interaction testing unit in Malaysia
ALPS•Alps Group launched a Pharmaco-Interaction laboratory unit at its MyGenome subsidiary in Kuala Lumpur, offering CYP450 inhibitory IC50 testing across seven enzyme isoforms that metabolize approximately 90% of marketed clinical drugs.
1. Testing services launch
Alps Group launched the Pharmaco-Interaction laboratory unit at its MyGenome subsidiary in Kuala Lumpur, Malaysia, expanding its commercial testing services. The unit offers CYP450 inhibitory IC50 testing for drug interactions, targeting herbal and supplement manufacturers, pharmaceutical companies and research institutions.
2. Testing scope
Testing covers seven major enzyme isoforms responsible for metabolizing approximately 90% of marketed clinical drugs.
